This content is in French.
Localized lung cancer: a new triplet therapy shows promising signs of efficacy
29 avril 2026
By Elodie Vaz | Published on April 29, 2026 | 4 min readPresented during an oral session at the American Association for Cancer Research (AACR) congress held from April 17 to 22 by Prof. Fabrice Barlesi, the phase II MATISSE study brings new hope for the management of localized and operable non–small cell lung cancer (NSCLC). By adding an innovative molecule to the current standard combining chemo
By Elodie Vaz | Published on April 29,
2026 | 4 min read
Presented during an oral session at the American Association for Cancer Research (AACR) congress held from April 17 to 22 by Prof. Fabrice Barlesi, the phase II MATISSE study brings new hope for the management of localized and operable non–small cell lung cancer (NSCLC). By adding an innovative molecule to the current standard combining chemotherapy and immunotherapy, this triplet strategy has shown encouraging early clinical results, particularly in certain patient subgroups.
Presented during an oral session at the American Association for Cancer Research (AACR) congress held from April 17 to 22 by Prof. Fabrice Barlesi, the phase II MATISSE study brings new hope for the management of localized and operable non–small cell lung cancer (NSCLC). By adding an innovative molecule to the current standard combining chemotherapy and immunotherapy, this triplet strategy has shown encouraging early clinical results, particularly in certain patient subgroups.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
View the source
